ADC Therapeutics SA Finance Costs
ADC Therapeutics SA (ADCT) reported Finance Costs of $12.94 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:FinanceCosts · last filed 2023-11-07
- ADC Therapeutics SA finance costs for the quarter ending 2023-09-30 was $12.94M, a 13.97% increase year-over-year.
- ADC Therapeutics SA finance costs for the quarter ending 2023-06-30 was $15.86M, a 80.17% increase year-over-year.
- ADC Therapeutics SA finance costs for the quarter ending 2023-03-31 was $10.42M, a 13.02% increase year-over-year.
- ADC Therapeutics SA finance costs for the quarter ending 2022-12-31 was $7.55M, a 20.69% decline year-over-year.
| Period end | Finance Costs 3 month | Finance Costs 6 month | Finance Costs 9 month | Finance Costs 12 month |
|---|---|---|---|---|
| 2023-09-30 | $12.94M 6-K · filed 2023-11-07 | $28.80M derived: sum of 2 quarters · filed 2023-11-07 | $38.65M 6-K · filed 2023-11-07 | $46.77M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $15.86M 6-K · filed 2023-08-08 | $26.14M 6-K · filed 2023-08-08 | $33.82M derived: sum of 3 quarters · filed 2023-08-08 | $45.18M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $10.42M 6-K · filed 2023-05-09 | $17.97M derived: sum of 2 quarters · filed 2023-05-09 | $29.32M derived: sum of 3 quarters · filed 2023-11-07 | $38.12M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $7.55M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $18.91M derived: sum of 2 quarters · filed 2023-11-07 | $27.71M derived: sum of 3 quarters · filed 2023-11-07 | $36.92M 20-F · filed 2023-03-15 |
| 2022-09-30 | $11.36M 6-K · filed 2023-11-07 | $20.16M derived: sum of 2 quarters · filed 2023-11-07 | $29.37M 6-K · filed 2023-11-07 | $38.89M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $8.80M 6-K · filed 2023-08-08 | $18.02M 6-K · filed 2023-08-08 | $27.54M derived: sum of 3 quarters · filed 2023-08-08 | $31.80M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $9.22M 6-K · filed 2023-05-09 | $18.74M derived: sum of 2 quarters · filed 2023-05-09 | $23.00M derived: sum of 3 quarters · filed 2023-05-09 | $25.56M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $9.52M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $13.79M derived: sum of 2 quarters · filed 2023-03-15 | $16.34M derived: sum of 3 quarters · filed 2023-03-15 | $18.34M 20-F · filed 2023-03-15 |
| 2021-09-30 | $4.26M 6-K · filed 2022-11-08 | $6.82M derived: sum of 2 quarters · filed 2022-11-08 | $8.82M 6-K · filed 2022-11-08 | $10.87M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $2.56M 6-K · filed 2022-08-09 | $4.55M 6-K · filed 2022-08-09 | $6.60M derived: sum of 3 quarters · filed 2023-03-15 | $8.54M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $2.00M 6-K · filed 2022-05-09 | $4.05M derived: sum of 2 quarters · filed 2023-03-15 | $5.99M derived: sum of 3 quarters · filed 2023-03-15 | $6.88M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $2.05M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $3.99M derived: sum of 2 quarters · filed 2023-03-15 | $4.88M derived: sum of 3 quarters · filed 2023-03-15 | $4.93M 20-F · filed 2023-03-15 |
| 2020-09-30 | $1.94M 6-K · filed 2021-11-02 | $2.84M derived: sum of 2 quarters · filed 2021-11-02 | $2.88M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $897.00K 6-K · filed 2021-08-03 | $939.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $42.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $156.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $0.00 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |